Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.
Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen
View HTML
Toggle Summary Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms
CAS Group Supports Improved Deal Company Currently has Sufficient Votes to Approve Merger ATLANTA , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February
View HTML
Toggle Summary Vaxart Provides Merger Update View HTML
Toggle Summary Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders
Aviragen Stockholders to Own 49% of Combined Company, Up from 40% Under the Previous Agreement
View HTML
Toggle Summary Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018
Board of Directors Unanimously Recommends that Aviragen Stockholders Vote FOR the Vaxart Merger
View HTML
Toggle Summary Aviragen Provides New Information Supporting Vote FOR Vaxart Merger
Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA , Jan. 31, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study
Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study  
View HTML
Toggle Summary Vaxart Issues Statement Regarding Proposed Merger With Aviragen View HTML
Toggle Summary Aviragen Comments on ISS Report
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed Merger with Vaxart ATLANTA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aviragen
View HTML
Toggle Summary Aviragen Therapeutics Issues Letter to Stockholders
Reiterates Benefits of Proposed Merger with Vaxart   Urges All Aviragen Stockholders to Vote FOR the Proposed Merger on the WHITE Proxy Card Today ATLANTA , Jan. 24, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued a letter to stockholders urging them to vote FOR
View HTML
Toggle Summary Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart
Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ATLANTA , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
ATLANTA , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4
View HTML
Toggle Summary Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results
ATLANTA , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. "Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive
View HTML
Toggle Summary Aviragen Therapeutics and Vaxart Enter into Merger Agreement
  Merged Company to Focus on Development of Antiviral Vaccines and Therapeutics  Based on Proprietary Delivery Technology Platform Conference Call to be Held Today at 8:30 AM ET  ATLANTA and SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Aviragen Therapeutics and Vaxart Enter into Merger Agreement View HTML

Log In

Create an account